Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Freedman

Pediatric Endocrinology Pembroke Pines, FL Medical Doctor

NPI 1588701379 CMS profile 71539

601 N Flamingo Rd Ste 207, Pembroke Pines, FL 33028

Open in the dashboard

General payments

$70,773

153 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,500 paid to institutions, not to them · program year 2022

Through program year 2025, Samuel Freedman of Pembroke Pines, FL is reported in the CMS Open Payments database as having received $70,773 across 153 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,092 24
2024 General $5,516 14
2023 General $4,192 12
2022 General $4,321 12
2021 General $14,430 18
2020 General $24,166 29
2019 General $15,056 44

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Freedman
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Samuel Freedman were reported at $3,092. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Samuel Freedman Pediatric Endocrinology median Middle half National median
2019 $15,056 $196 $68–$845 $163
2020 $24,166 $124 $37–$722 $114
2021 $14,430 $134 $35–$691 $132
2022 $4,321 $177 $47–$726 $149
2023 $4,192 $236 $75–$887 $160
2024 $5,516 $259 $91–$979 $164
2025 $3,092 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $39,528 58 payments
  2. AbbVie, Inc. $17,397 67 payments
  3. BioMarin Pharmaceutical Inc. $5,350 2 payments
  4. Pfizer Inc. $4,265 17 payments
  5. Ascendis Pharma, Inc. $4,143 5 payments
  6. Neurocrine Biosciences, Inc. $35 1 payment
  7. Arbor Pharmaceuticals, Inc. $33 2 payments
  8. EMD Serono, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $42,759 26 payments
  2. Consulting Fee $24,600 7 payments
  3. Food and Beverage $2,273 107 payments
  4. Travel and Lodging $1,106 10 payments
  5. Education $36 3 payments
Products named General payments · program years 2019–2025
  1. Norditropin Growth Hormone $21,837 20 payments
  2. Norditropin Growth Hormone $14,346 23 payments
  3. LUPRON DEPOT Endocrinology $12,102 13 payments
  4. VOXZOGO 1.2mg $5,350 2 payments
  5. LUPRON DEPOT Endocrinology $4,924 25 payments
  6. SKYTROFA $4,143 5 payments
  7. NGENLA $3,960 1 payment
  8. Sogroya $2,912 13 payments
  9. Norditropin Growth Hormone $434 2 payments
  10. GENOTROPIN $305 16 payments
  11. Other $556 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

153 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record